LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Home・Listă Acțiuni・Puma Biotechnology Inc

Puma Biotechnology Inc

Închisă

SectorSănătate

7.02 0.57

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

6.82

Maxim

7.08

Indicatori cheie
By Trading Economics
Venit	-16M -3.8M
Vânzări	-31M 45M
P/E Medie Sector	14.188 49.701
EPS	-0.04
Marjă de profit	-8.375
Angajați	179
EBITDA	-28M -1.3M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	-28.47% downside

Dividende
By Dow Jones
Următoarele câștiguri	6 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-37M 347M
Deschiderea anterioară	6.45
Închiderea anterioară	7.02

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

3.07 / 3.075 Suport & Rezistență

Puma Biotechnology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

21 mai 2026, 22:48 UTC

Achiziții, Fuziuni, Preluări

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 mai 2026, 16:49 UTC

Câștiguri

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 mai 2026, 16:26 UTC

Principalele dinamici ale pieței

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 mai 2026, 23:55 UTC

Câștiguri

Lenovo Group Fourth-Quarter Net Soars on Strong AI Demand

21 mai 2026, 23:51 UTC

Market Talk

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 mai 2026, 23:37 UTC

Câștiguri

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 mai 2026, 23:37 UTC

Câștiguri

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 mai 2026, 23:37 UTC

Câștiguri

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 mai 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 mai 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

21 mai 2026, 23:30 UTC

Market Talk

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 mai 2026, 22:33 UTC

Achiziții, Fuziuni, Preluări

Conduent to Sell Public Transit Business to Modaxo for $164M

21 mai 2026, 21:53 UTC

Câștiguri

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 mai 2026, 21:02 UTC

Câștiguri

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 mai 2026, 20:55 UTC

Câștiguri

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 mai 2026, 20:30 UTC

Acțiuni populare

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 mai 2026, 20:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 mai 2026, 20:20 UTC

Market Talk

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 mai 2026, 20:20 UTC

Câștiguri

Webull 1Q Adj EPS 3c >BULL

21 mai 2026, 20:20 UTC

Câștiguri

Webull 1Q Rev $159.9M >BULL

21 mai 2026, 20:18 UTC

Market Talk

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 mai 2026, 20:18 UTC

Câștiguri

Webull 1Q Loss/Shr 4c

21 mai 2026, 19:43 UTC

Market Talk

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 mai 2026, 18:58 UTC

Câștiguri

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 mai 2026, 18:15 UTC

Market Talk

Gold Higher For Second Consecutive Day -- Market Talk

21 mai 2026, 17:40 UTC

Market Talk

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 mai 2026, 17:04 UTC

Market Talk

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 mai 2026, 17:01 UTC

Câștiguri

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 mai 2026, 16:20 UTC

Market Talk

Câștiguri

Stellantis Targets Distant but Constructive -- Market Talk

Comparație

Modificare preț

Puma Biotechnology Inc Așteptări

Obiectiv de preț

By TipRanks

-28.47% jos

Prognoză pe 12 luni

Medie 5 USD -28.47%

Maxim 5 USD

Minim 5 USD

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPuma Biotechnology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

1 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 1 analiști care au acordat evaluări ale acțiunilor Puma Biotechnology Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

3.07 / 3.075Suport & Rezistență

Recent bullish events outweigh bearish events.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.